Literature DB >> 18799936

A single dose of anti-D immunoglobulin raises platelet count as efficiently as intravenous immunoglobulin in newly diagnosed immune thrombocytopenic purpura in Korean children.

Dong Woo Son1, In-sang Jeon, Sung Wan Yang, Sang Hee Cho.   

Abstract

OBJECTIVE: The aim of this study is to compare the efficacy and safety of a single dose of anti-D immunoglobulin (anti-D) at 50 mug/kg to intravenous immunoglobulin (IVIG) in Korean children with acute immune thrombocytopenic purpura (ITP).
METHODS: We performed this study prospectively by randomly administering 2 consecutive doses of IVIG at a dose of 1.0 g/kg/dor a single dose of anti-D at 50 microg/kg to children upon initial diagnosis of acute ITP. The platelet count and adverse events, including hemoglobin concentration, were then serially evaluated, and the responses were compared.
RESULTS: The likelihood of having a platelet count greater than 20x10/mm after 3 days of treatment in the IVIG and anti-D group was 93% and 92%, respectively. In addition, hemoglobin concentration in the anti-D group had declined more than that of the IVIG group (1.49 g/dL vs. 0.80 g/dL, P=0.014) 3 days after treatment. Fever, chills, and headache occurred less frequently in the anti-D group than the IVIG group, however, this difference was not statistically significant (25% vs. 45%, P=0.494).
CONCLUSIONS: A single dose of 50 microg/kg of anti-D raised platelet count as efficiently as IVIG in newly diagnosed cases of ITP in Korean children. Although 50 microg/kg of anti-D had a greater effect on the hemoglobin concentration than IVIG, the adverse effects were found to be acceptable, and no serious events were observed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799936     DOI: 10.1097/MPH.0b013e31817541ba

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

Review 1.  RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Authors:  Jenny M Despotovic; Michele P Lambert; Jay H Herman; Terry B Gernsheimer; Keith R McCrae; Michael D Tarantino; James B Bussel
Journal:  Transfusion       Date:  2011-10-07       Impact factor: 3.157

2.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

3.  Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura.

Authors:  Muhittin Celik; Ali Bulbul; Gönül Aydogan; Deniz Tugcu; Emrah Can; Sinan Uslu; Mesut Dursun
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

Review 4.  Management of immune thrombocytopenia: Korean experts recommendation in 2017.

Authors:  Jun Ho Jang; Ji Yoon Kim; Yeung-Chul Mun; Soo-Mee Bang; Yeon Jung Lim; Dong-Yeop Shin; Young Bae Choi; Ho-Young Yhim; Jong Wook Lee; Hoon Kook
Journal:  Blood Res       Date:  2017-12-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.